A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety.

Stanford Investigator(s)


Primary Contact:
Illisha Rajasansi
(650) 421-1397